The future of Cambridge-based immunology biotech Idera is murky after a planned merger with drug developer BioCryst fell through this week.
The two companies had announced plans for a merger in January. Under the agreement, Idera (Nasdaq: IDRA) planned to close its Cambridge office and move its 36 employees to offices in Pennsylvania and Alabama. Idera’s CEO Vincent Milano was also set to lead the combined company.
BioCryst’s (Nasdaq: BCRX) shareholders voted against the merger during a meeting…
Source: Boston Biz